|
1
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Labianca R, Nordlinger B, Beretta GD,
Mosconi S, Mandalà M, Cervantes A and Arnold D: ESMO Guidelines
Working Group: Early colon cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
24(Suppl 6): vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clinical practice guidelines in oncology
(NCCN Guidelines): Colon cancer. Version 3.2015. National
comprehensive cancer network (Fort Washington). 2015.
|
|
4
|
Chen WQ, Zeng HM, Zheng RS, Zhang SW and
He J: Cancer incidence and mortality in china, 2007. Chin J Cancer
Res. 24:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hylton N: Dynamic contrast-enhanced
magnetic resonance imaging as an imaging biomarker. J Clin Oncol.
24:3293–3298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jackson A, O'Connor JP, Parker GJ and
Jayson GC: Imaging tumor vascular heterogeneity and angiogenesis
using dynamic contrast-enhanced magnetic resonance imaging. Clin
Cancer Res. 13:3449–3459. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cha S: Perfusion MR imaging: Basic
principles and clinical applications. Magn Reson Imaging Clin N Am.
11:403–413. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villers A, Puech P, Mouton D, Leroy X,
Ballereau C and Lemaitre L: Dynamic contrast enhanced, pelvic
phased array magnetic resonance imaging of localized prostate
cancer for predicting tumor volume: Correlation with radical
prostatectomy findings. J Urol. 176:2432–2437. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haider MA, Chung P, Sweet J, Toi A,
Jhaveri K, Ménard C, Warde P, Trachtenberg J, Lockwood G and
Milosevic M: Dynamic contrast-enhanced magnetic resonance imaging
for localization of recurrent prostate cancer after external beam
radiotherapy. Int J Radiat Oncol Biol Phys. 70:425–430. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Puech P, Potiron E, Lemaitre L, Leroy X,
Haber GP, Crouzet S, Kamoi K and Villers A: Dynamic
contrast-enhanced-magnetic resonance imaging evaluation of
intraprostatic prostate cancer: Correlation with radical
prostatectomy specimens. Urology. 74:1094–1099. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu K, Xie P, Peng W and Zhou Z: Dynamic
contrast-enhanced magnetic resonance imaging for pancreatic ductal
adenocarcinoma at 3.0-T magnetic resonance: Correlation with
histopathology. J Comput Assist Tomogr. 39:13–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hahn OM, Yang C, Medved M, Karczmar G,
Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ and Stadler
WM: Dynamic contrast-enhanced magnetic resonance imaging
pharmacodynamic biomarker study of sorafenib in metastatic renal
carcinoma. J Clin Oncol. 26:4572–4578. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu G, Rugo HS, Wilding G, McShane TM,
Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, et al:
Dynamic contrast-enhanced magnetic resonance imaging as a
pharmacodynamic measure of response after acute dosing of
AG-013736, an oral angiogenesis inhibitor, in patients with
advanced solid tumors: Results from a phase I study. J Clin Oncol.
23:5464–5473. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barrett T, Davidson SR, Wilson BC,
Weersink RA, Trachtenberg J and Haider MA: Dynamic contrast
enhanced MRI as a predictor of vascular-targeted photodynamic focal
ablation therapy outcome in prostate cancer post-failed external
beam radiation therapy. Can Urol Assoc J. 8:E708–E714. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morgan B, Thomas AL, Drevs J, Hennig J,
Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, et al:
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker
for the pharmacological response of PTK787/ZK 222584, an inhibitor
of the vascular endothelial growth factor receptor tyrosine
kinases, in patients with advanced colorectal cancer and liver
metastases: Results from two phase I studies. J Clin Oncol.
21:3955–3964. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tofts PS, Brix G, Buckley DL, Evelhoch JL,
Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et
al: Estimating kinetic parameters from dynamic contrast-enhanced
T(1)-weighted MRI of a diffusable tracer: Standardized quantities
and symbols. J Magn Reson Imaging. 10:223–232. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Franiel T, Hamm B and Hricak H: Dynamic
contrast-enhanced magnetic resonance imaging and pharmacokinetic
models in prostate cancer. Eur Radiol. 21:616–626. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bosman FT: World Health Organization:
International agency for research on cancer. WHO classification of
tumours of the digestive system. International Agency for Research
on Cancer (Lyon). 2010.PubMed/NCBI
|
|
19
|
Vriens D, van Laarhoven HW, van Asten JJ,
Krabbe PF, Visser EP, Heerschap A, Punt CJ, de Geus-Oei LF and Oyen
WJ: Chemotherapy response monitoring of colorectal liver metastases
by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG
PET metabolic rate. J Nucl Med. 50:1777–1784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Furuya M and Yonemitsu Y: Cancer
neovascularization and proinflammatory microenvironments. Curr
Cancer Drug Targets. 8:253–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Teifke A, Behr O, Schmidt M, Victor A,
Vomweg TW, Thelen M and Lehr HA: Dynamic MR imaging of breast
lesions: Correlation with microvessel distribution pattern and
histologic characteristics of prognosis. Radiology. 239:351–360.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan Y, Kuai XP, Chen XS and Tao XF:
Assessment of dynamic contrast-enhanced magnetic resonance imaging
in the differentiation of malignant from benign orbital masses. Eur
J Radiol. 82:1506–1511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nadrljanski M, Maksimović R,
Plešinac-Karapandžić V, Nikitović M, Marković-Vasiljković B and
Milošević Z: Positive enhancement integral values in dynamic
contrast enhanced magnetic resonance imaging of breast carcinoma:
Ductal carcinoma in situ vs. invasive ductal carcinoma. Eur
J Radiol. 83:1363–1367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S, Delproposto Z, Wang H, Ding X, Ji
C, Wang B and Xu M: Differentiation of breast cancer from
fibroadenoma with dual-echo dynamic contrast-enhanced MRI. PLoS
One. 8:e677312013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishiyama M, Richards T, Parvathaneni U and
Anzai Y: Dynamic contrast-enhanced magnetic resonance imaging in
Head and Neck Cancer: Differentiation of new H&N cancer,
recurrent disease and benign post-treatment changes. Clin Imaging.
39:566–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tuncbilek N, Karakas HM and Altaner S:
Dynamic MRI in indirect estimation of microvessel density,
histologic grade and prognosis in colorectal adenocarcinomas. Abdom
Imaging. 29:166–172. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hong HS, Kim SH, Park HJ, Park MS, Kim KW,
Kim WH, Kim NK, Lee JM and Cho HJ: Correlations of dynamic
contrast-enhanced magnetic resonance imaging with morphologic,
angiogenic and molecular prognostic factors in rectal cancer.
Yonsei Med J. 54:123–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
